Last checked at 
BioPharma, which began trading on March 30, 2017, on
Total income in the period from October 24, 2016, to December 31, 2017, was
BioPharma said, with total commitments of
The life sciences industry has done well over the past few months, it said, with the New York Stock Exchange Biotechnology index rising 18% since April and 37% since the start of 2017.
BioPharma also announced Thursday it is to place 300 million C shares at a price of
The joint bookrunners for the raise are Merrill Lynch International, Goldman Sachs International, and JPMorgan Securities PLC.
Chief Executive Pedro Gonzalez de Cosio said: "This has been a highly successful first year for BioPharma Credit and we are delighted with the progress since the initial listing in March 2017. Since the IPO, the company has made five investments, deploying
"BioPharma Credit remains uniquely positioned to generate uncorrelated long-term shareholder returns, predominantly in the form of sustainable income distributions from exposure to the life sciences industry."
Shares were up 1.1% on Thursday at a price of
